Mizuho Initiates Coverage On Cerevel Therapeutics Hldg with Neutral Rating, Announces Price Target of $30

Mizuho analyst Graig Suvannavejh initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral rating and announces Price Target of $30.

Mizuho analyst Graig Suvannavejh initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral rating and announces Price Target of $30.

Total
0
Shares
Related Posts